Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Three decades after the first Transcatheter Cardiovascular Therapeutics conference, TCT.18’s organizers are moving “toward a more practical approach,” says Cardiovascular Research Foundation CEO Juan Granada, MD.
Is practice variation a real problem or a passing trend? Which metrics matter? Are there practical approaches healthcare leaders should use to tackle variation and, if so, how can they get their teams on board? Cardiologists and administrators weigh in.
Is the 30-day readmissions metric for PCI fair or fatally flawed? The answer could have considerable financial, clinical and reputational impact for hospitals and physicians.
Despite limitations, hospital rankings have become an essential tool as clinicians and executives set goals for their institutions and strive to achieve them. And patients take notice, too.
